Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Current Deferred Revenue (2020 - 2025)

Barinthus Biotherapeutics' Current Deferred Revenue history spans 5 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 19.68% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, down 19.68%, while the annual FY2025 figure was $1.4 million, 19.68% down from the prior year.
  • Current Deferred Revenue reached $1.4 million in Q4 2025 per BRNS's latest filing, roughly flat from $1.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.0 million in Q3 2024 to a low of $111000.0 in Q3 2022.
  • Average Current Deferred Revenue over 4 years is $879266.7, with a median of $839000.0 recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: crashed 53.18% in 2022, then skyrocketed 81.76% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $182000.0 in 2021, then tumbled by 39.01% to $111000.0 in 2022, then surged by 1465.77% to $1.7 million in 2024, then dropped by 19.68% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Current Deferred Revenue are $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.5 million (Q2 2025).